Practical guidelines for diagnosis and therapy of restless legs syndrome;Praktische diagnostik und therapie des restless-legs-syndroms

Nervenarzt

Volumn 85, Issue 1, 2014, Pages 9-18

  Krenzer, M ^a   Oertel, W ^a   Trenkwalder, C ^b  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b Paracelsus Elena Klinik Kassel   (Germany)

Author keywords

Diagnosis; Dopamine; Pain; Restless legs syndrome; Therapy

Indexed keywords

ANTICONVULSIVE AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; OPIATE;

ANTICONVULSANT THERAPY; ARTICLE; COMORBIDITY; HUMAN; OUTPATIENT; PRACTICE GUIDELINE; QUALITY OF LIFE; RESTLESS LEGS SYNDROME;

ANALGESICS, OPIOID; ANTICONVULSANTS; DIAGNOSIS, DIFFERENTIAL; DOPAMINE AGENTS; HUMANS; PAIN; RESTLESS LEGS SYNDROME;

EID: 84898411256     PISSN: 00282804     EISSN: 14330407     Source Type: Journal    
DOI: 10.1007/s00115-013-3888-3     Document Type: Article

References (48)

1. Allen R, Chen C, Soaita A et al (2010) A randomized, double-blind, 6-week, dose-ranging study of pregabalin in patients with restless legs syndrome. Sleep Med 11:512-519
2. Allen RP, Adler CH, Du W et al (2011) Clinical efficacy and safety of IV ferric carboxymaltose (FCM) treatment of RLS: a multi-centred, placebo-controlled preliminary clinical trial. Sleep Med 12: 906-913
3. Allen RP, Barker PB, Horska A, Earley CJ (2013) Thalamic glutamate/glutamine in restless legs syndrome: increased and related to disturbed sleep. Neurology 80:2028-2034
4. Allen RP, Picchietti D, Hening WA et al (2003) Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 4:101-119
5. Benes H, Garcia-Borreguero D, Ferini-Strambi L et al (2012) Augmentation in the treatment of restless legs syndrome with transdermal rotigotine. Sleep Med 13:589-597
6. Benes H, Kohnen R (2009) Validation of an algorithm for the diagnosis of Restless Legs Syndrome: the Restless Legs Syndrome-Diagnostic Index (RLS-DI). Sleep Med 10:515-523
7. Berger K, Kurth T (2007) RLS epidemiology - frequencies, risk factors and methods in population studies. Mov Disord 22(Suppl 18):S420-S423
8. Berger K, Eckardstein A von, Trenkwalder C et al (2002) Iron metabolism and the risk of restless legs syndrome in an elderly general population - the MEMO-Study. J Neurol 249:1195-1199
9. Chabli A, Michaud M, Montplaisir J (2000) Periodic arm movements in patients with the restless legs syndrome. Eur Neurol 44:133-138
10. Collado-Seidel V, Kohnen R, Samtleben W et al (1998) Clinical and biochemical findings in uremic patients with and without restless. Am J Kidney Dis 31:324-328
11. Connor JR, Boyer PJ, Menzies SL et al (2003) Neuropathological examination suggests impaired brain iron acquisition in restless legs syndrome. Neurology 61:304-309
12. Cuellar NG (2012) The psychopharmacological management of RLS in psychiatric conditions: a review of the literature. J Am Psychiatr Nurses Assoc 18:214-225
13. DeAndrade MP, Johnson RL Jr, Unger EL et al (2012) Motor restlessness, sleep disturbances, thermal sensory alterations and elevated serum iron levels in Btbd9 mutant mice. Hum Mol Genet 21:3984-3992
14. Eisensehr I, Wetter TC, Linke R et al (2001) Normal IPT and IBZM SPECT in drug-naive and levodopa- treated idiopathic restless legs syndrome. Neurology 57:1307-1309
15. Ferini-Strambi L, Walters AS, Sica D (2013) The relationship among restless legs syndrome (Willis-Ekbom Disease), hypertension, cardiovascular disease, and cerebrovascular disease. J Neurol
16. Garcia-Borreguero D, Hogl B, Ferini-Strambi L et al (2012) Systematic evaluation of augmentation during treatment with ropinirole in restless legs syndrome (Willis-Ekbom disease): results from a prospective, multicenter study over 66 weeks. Mov Disord 27:277-283
17. Garcia-Borreguero D, Kohnen R, Hogl B et al (2007) Validation of the Augmentation Severity Rating Scale (ASRS): a multicentric, prospective study with levodopa on restless legs syndrome. Sleep Med 8:455-463
18. Garcia-Borreguero D, Kohnen R, Silber MH et al (2013) The long-term treatment of restless legs syndrome/Willis-Ekbom disease: evidence-based guidelines and clinical consensus best practice guidance: a report from the International Restless Legs Syndrome Study Group. Sleep Med 14: 675-684
19. Garcia-Borreguero D, Larrosa O, Llave Y de la et al (2002) Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study. Neurology 59:1573-1579
20. Grote L, Leissner L, Hedner J, Ulfberg J (2009) A randomized, double-blind, placebo controlled, multi-center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome. Mov Disord 24:1445-1452
21. Happe S, Vennemann M, Evers S, Berger K (2008) Treatment wish of individuals with known and unknown restless legs syndrome in. J Neurol 255:1365-1371
22. Hattan E, Chalk C, Postuma RB (2009) Is there a higher risk of restless legs syndrome in peripheral neuropathy? Neurology 72:955-960
23. Hening WA, Allen RP, Ondo WG et al (2010) Rotigotine improves restless legs syndrome: a 6-month randomized, double-blind, placebo-controlled trial in the United States. Mov Disord 25: 1675-1683
24. Hening WA, Allen RP, Washburn M et al (2009) The four diagnostic criteria for Restless Legs Syndrome are unable to exclude. Sleep Med 10:976-981
25. Hening WA, Walters AS, Wagner M et al (1999) Circadian rhythm of motor restlessness and sensory symptoms in the idiopathic restless legs syndrome. Sleep 22:901-912
26. Hogl B, Garcia-Borreguero D, Kohnen R et al (2010) Progressive development of augmentation during long-term treatment with levodopa in restless legs syndrome: results of a prospective multi-center study. J Neurol 257:230-237
27. Hogl B, Garcia-Borreguero D, Trenkwalder C et al (2011) Efficacy and augmentation during 6 months of double-blind pramipexole for restless legs syndrome. Sleep Med 12:351-360
28. Kavanagh D, Siddiqui S, Geddes CC (2004) Restless legs syndrome in patients on dialysis. Am J Kidney Dis 43:763-771
29. Manconi M, Govoni V, De Vito A et al (2004) Restless legs syndrome and pregnancy. Neurology 63:1065-1069
30. Michaud M, Soucy JP, Chabli A et al (2002) SPECT imaging of striatal pre- and postsynaptic dopaminergic status in restless legs syndrome with periodic leg movements in sleep. J Neurol 249:164-170
31. Montplaisir J, Boucher S, Nicolas A et al (1998) Immobilization tests and periodic leg movements in sleep for the diagnosis of restless leg syndrome. Mov Disord 13:324-329
32. Oertel W, Trenkwalder C, Benes H et al (2011) Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study. Lancet Neurol 10:710-720
33. Oertel WH, Trenkwalder C, Zucconi M et al (2007) State of the art in restless legs syndrome therapy: practice recommendations for treating restless legs syndrome. Mov Disord 22(Suppl 18): S466-S475
34. Patton SM, Ponnuru P, Snyder AM et al (2011) Hypoxia- inducible factor pathway activation in restless legs syndrome patients. Eur J Neurol 18: 1329-1335
35. Paulus W, Trenkwalder C (2006) Less is more: pathophysiology of dopaminergic-therapy-related augmentation in restless legs syndrome. Lancet Neurol 5:878-886
36. Schattschneider J, Bode A, Wasner G et al (2004) Idiopathic restless legs syndrome: abnormalities in central somatosensory processing. J Neurol 251:977-982
37. Schmidauer C, Sojer M, Seppi K et al (2005) Transcranial ultrasound shows nigral hypoechogenicity in restless legs syndrome. Ann Neurol 58:630-634
38. Schormair B, Kemlink D, Roeske D et al (2008) PTPRD (protein tyrosine phosphatase receptor type delta) is associated with restless legs syndrome. Nat Genet 40:946-948
39. Silver N, Allen RP, Senerth J, Earley CJ (2011) A 10-year, longitudinal assessment of dopamine agonists and methadone in the treatment of restless legs syndrome. Sleep Med 12:440-444
40. Stefansson H, Rye DB, Hicks A et al (2007) A genetic risk factor for periodic limb movements in sleep. N Engl J Med 357:639-647
41. Stiasny-Kolster K, Kohnen R, Moller JC et al (2006) Validation of the "L-DOPA test" for diagnosis of restless legs syndrome. Mov Disord 21:1333-1339
42. Stiasny-Kolster K, Pfau DB, Oertel WH et al (2013) Hyperalgesia and functional sensory loss in restless legs syndrome. Pain 154:1457-1463
43. Sun ER, Chen CA, Ho G et al (1998) Iron and the restless legs syndrome. Sleep 21:371-377
44. Szentkiralyi A, Volzke H, Hoffmann W et al (2013) The relationship between depressive symptoms and restless legs syndrome in two prospective cohort studies. Psychosom Med 75:359-365
45. Trenkwalder C, Benes H, Buschmann H et al (2012) S1-Leitlinie für Diagnostik und Therapie in der Neurologie Restless-Legs-Syndrom (RLS) und Periodic Limb Movement Disorders (PLMD). In: Diener H-C (Hrsg) Leitlinien für Diagnostik und Therapie in der Neurologie. Thieme, Stuttgart
46. Trenkwalder C, Benes H, Grote L et al (2013) Oxycodone/ Naloxone PR for efficient treatment of severe RLS after failure of previous medications - a double-blind, randomized, placebo-controlled study with open-label extension. Lancet Neurol (im Druck)
47. Trenkwalder C, Benes H, Grote L et al (2007) Cabergoline compared to levodopa in the treatment of patients with severe restless legs syndrome: results from a multi-center, randomized, active controlled trial. Mov Disord 22:696-703
48. Trenkwalder C, Benes H, Poewe W et al (2008) Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 7:595-604